NNovartis Read More Beyond Breast Cancer: Making Lived Experiences More Visible2026-09-29 For many people impacted by breast cancer, the experience does not end when treatment ends. Questions about recurrence,…
NNovartis Read More Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials2026-09-01 Ad hoc announcement pursuant to Art. 53 LR REMODEL-1/-2 trials met their primary endpoint, significantly reducing…